Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Frontiers in Oncology|July 3, 2013
Cancer stem cells in pediatric sarcomasFilemon S Dela Cruz
Nature Communications|January 2, 2025
A Bayesian active learning platform for scalable combination drug screensChristopher Tosh, Mauricio Tec, Jessica B White, et al.
Blood Advances|April 1, 2021
ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia presenting in an infant: an entity distinct from JMMLBarbara Spitzer, Filemon S Dela Cruz, Glorymar D Ibanez Sanchez, et al.
Molecular Cancer Therapeutics|September 5, 2021
Translational Strategies for Repotrectinib in NeuroblastomaTara J O'Donohue, Glorymar Ibáñez, Diego Ferreira Coutinho, et al.
Biorxiv : the Preprint Server for Biology|February 17, 2023
Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapyYaniv Kazansky, Daniel Cameron, Helen S Mueller, et al.
Cancer Discovery|February 5, 2024
Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination TherapyYaniv Kazansky, Daniel Cameron, Helen S Mueller, et al.
Biorxiv : the Preprint Server for Biology|May 20, 2024
Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomasYaniv Kazansky, Helen S Mueller, Daniel Cameron, et al.
Cold Spring Harbor Molecular Case Studies|May 6, 2016
Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcomaSarah Tannenbaum-Dvir, Julia L Glade Bender, Alanna J Church, et al.
Molecular Cancer Therapeutics|June 17, 2017
Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt LymphomaLisa Giulino-Roth, Herman J van Besien, Tanner Dalton, et al.
The Journal of Clinical Investigation|August 12, 2025
Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomasYaniv Kazansky, Helen S Mueller, Daniel Cameron, et al.
Pageof 5